Ayijiang Yisimayi

This paper predicts SARS-CoV-2 RBD evolution using deep mutational scanning to identify broadly neutralizing antibodies effective against existing and prospective variants.

This study analyzes the humoral immune response to SARS-CoV-2 XBB and JN.1 lineages, showing JN.1 elicits superior neutralization and highlights the need for JN.1-based vaccine boosters.

The paper investigates how Omicron-specific naive B cell maturation after breakthrough infection alleviates immune imprinting from inactivated SARS-CoV-2 vaccines.

This study identifies ultra-potent Omicron-specific antibodies targeting the N1/N2 loop of the Spike NTD, which neutralize SARS-CoV-2 by competing with ACE2 and blocking S1 shedding, but are evaded by BA.2.86 and BA.2.87.1 sublineages.

This study assesses the antigenic properties and immune evasion of the SARS-CoV-2 variant BA.2.87.1, finding it less resistant to neutralizing antibodies than JN.1 but with compensatory deletions in the NTD.

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

This study shows that convergent evolution of SARS-CoV-2 XBB lineages at RBD positions 455-456 synergistically enhances antibody evasion and ACE2 binding through epistatic interactions.

The paper shows JN.1 outcompetes BA.2.86 and other variants by evading antibodies more effectively, despite reduced ACE2 binding.

This study characterizes the antigenic properties and infectivity of the SARS-CoV-2 BA.2.86 variant, finding it evades immune responses but has reduced infectivity compared to previous variants.